優彩資源(002998.SZ):可轉債部分募投項目建成投產
格隆匯10月9日丨優彩資源(002998.SZ)公佈,公司經中國證券監督管理委員會證監許可[2022]2957號文核准,公司於2022年12月14日向社會公開發行了面值總額6億元的可轉換公司債券,每張面值人民幣100元,發行數量為600.00萬張,期限6年。公司本次公開發行可轉債募集資金所投資的"年產8萬噸功能性複合型特種纖維技改項目"於近日建成,進入試產階段。
項目從試產運行到全面達產尚需一定時間,項目預期產能的釋放需要一個過程,即使全面達產,亦有可能面臨市場需求變化、市場競爭加劇、原料供應穩定性、原料價格大幅波動、能源供應穩定性等因素影響,存在項目效益不能如期實現等風險,敬請廣大投資者注意投資風險!
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.